Skip to main content

Cardinal Health vs McKesson: Strategic Comparison

Direct Answer

McKesson is bigger than Cardinal Health by revenue and profit: $403.4 billion in revenue and $4.76 billion in net income for fiscal 2026 (ended March 31, 2026), versus Cardinal Health's $254.2 billion in revenue and $1.71 billion in net income for its fiscal 2026 (ended June 30, 2026). McKesson also converts more of each sales dollar into profit, with a net margin near 1.18% against Cardinal Health's roughly 0.67%. Cardinal Health employs more people (63,900) than McKesson (about 43,000) despite having smaller revenue, so McKesson produces substantially more revenue per employee.

McKesson generates far more revenue with far fewer people: $403.4 billion in fiscal 2026 revenue from about 43,000 employees, versus Cardinal Health's $254.2 billion from 63,900 employees, a gap of roughly $9.4 million of revenue per McKesson employee against $4.0 million at Cardinal Health. McKesson is also the older company by a wide margin, tracing back to 1833 when John McKesson and Charles Olcott opened a New York drug-import business, while Cardinal Health began in 1971 as Robert D. Walter's Ohio food wholesaler, Cardinal Foods, and only entered pharmaceutical distribution in 1979. McKesson is led by CEO Brian S. Tyler, in the role since April 2019 after joining the company in 1997, while Cardinal Health has been run by CEO Jason M. Hollar since September 1, 2022, after he served as the company's CFO starting in May 2020. For their latest fiscal years, McKesson reported $403.430 billion in revenue and $4.762 billion in net income for the year ended March 31, 2026, while Cardinal Health reported $254.248 billion in revenue and $1.714 billion in net income for the year ended June 30, 2026.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldCardinal Health, Inc.McKesson Corporation
Latest annual revenue$254.2B (FY2026)$403.4B (FY2026)
Founded19711833
Employees63,90043,000
Market Cap$56.0BN/A
HeadquartersUnited StatesUnited States
Revenue / Employee$3.98M / employee$9.38M / employee
Valuation Multiple0.2x P/SN/A

Strategic Positioning

Business model and competitive context from the cited profiles

Cardinal Health, Inc. Strategic Vector

FY2026 Revenue Baseline

Cardinal Health, Inc.'s long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward specialty care acquisitions in oncology, gastroenterology, diabetes, and urology could transform margin profile, where cardinal Health has built physician-facing platforms in gastroenterology (GI Alliance, 71% stake for about $2. Concurrently, the organization focuses on navigating market pressures around structural generic drug deflation compresses the spread between acquisition cost and selling price, addressing environments where generic pharmaceutical prices generally decline over time as additional manufacturers enter the market, and the frequency of generic price appreciation events, where limited competition allows prices to rise, has decreased. By maintaining disciplined capital allocation and operational rigor, Cardinal Health, Inc. aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $3.98M / employee

McKesson Corporation Strategic Vector

FY2026 Revenue Baseline

McKesson's headline revenue is not the best measure of its moat. The more revealing indicators are distribution reliability, working-capital efficiency, segment operating profit, free cash flow, and the growth rate of oncology, multispecialty, and prescription-technology services.

Productivity: $9.38M / employee
Comparative Divergence: Cardinal Health, McKesson, and Cencora form the 'Big Three' that together control more than 90% of U.S. pharmaceutical wholesale distribution, and Cardinal Health alone handled more than $230 billion of U.S. drug distribution sales in fiscal 2026, roughly one-fourth of the overall market. The two companies increasingly compete through specialty physician-practice rollups: Cardinal Health closed The Specialty Alliance's roughly $1.9 billion Solaris Health urology acquisition in November 2025 on top of its GI Alliance stake, while McKesson added Florida Cancer Specialists' Core Ventures and PRISM Vision Holdings in 2025 to grow The US Oncology Network. McKesson is also diverging strategically by separating its Medical-Surgical Solutions business as 'Wellverse,' announced in 2026 after Apollo Funds bought a 13% stake, a divestiture path Cardinal Health has not followed as it keeps layering specialty units onto its wholesale base. Investor coverage of the pair, including head-to-head stock comparisons from Yahoo Finance and new 2026 research coverage from William Blair, treats Cardinal Health and McKesson as the two most directly compared names in U.S. drug distribution after Cencora.

Cardinal Health vs McKesson Market Share

Cardinal Health, Inc. market share
Cardinal Health is one of the three largest U.S. pharmaceutical wholesalers, with McKesson and Cencora; together the three handle the large majority of U.S. prescription drug distribution. It also runs the largest U.S. network of nuclear pharmacies.
McKesson Corporation market share
McKesson Corporation is one of the premier market leaders in Healthcare Distribution and Services, commanding substantial market share and strong brand equity across its core geographic operating regions.

Quick Stats Comparison

MetricCardinal Health, Inc.McKesson Corporation
Revenue$254.2B (FY2026)$403.4B (FY2026)
Founded19711833
HeadquartersDublin, Ohio, United StatesIrving, Texas, United States
Market Cap$56.0BN/A
Employees63,90043,000
Revenue / Employee$3.98M / employee$9.38M / employee
Valuation Multiple0.2x P/SN/A

Cardinal Health Revenue vs McKesson Revenue — Year by Year

YearCardinal Health, Inc.McKesson CorporationHigher reported revenue
2026$254.2B$403.4BMcKesson Corporation (approx. USD)
2025$222.6B$359.1BMcKesson Corporation (approx. USD)
2024$226.8B$309.0BMcKesson Corporation (approx. USD)
2023$205.0B$276.7BMcKesson Corporation (approx. USD)
2022$181.3B$264.0BMcKesson Corporation (approx. USD)

Business Model Breakdown

Overview: Cardinal Health, Inc. vs McKesson Corporation

This in-depth comparison examines Cardinal Health, Inc. and McKesson Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating McKesson Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and McKesson Corporation is widest.

On the headline numbers, annual revenue is $254.2B (FY2026) for Cardinal Health, Inc. and $403.4B (FY2026) for McKesson Corporation, while their respective market capitalizations stand at $56.0B and N/A. Both Cardinal Health, Inc. and McKesson Corporation are headquartered in United States. Their local markets and applicable rules may still differ.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network. The company is headquartered in Dublin, Ohio.

McKesson Corporation: McKesson is best understood as healthcare infrastructure. It moves medicines through a regulated network and supports providers and manufacturers with specialty distribution, oncology services, patient-access programs, technology, and medical supplies. The strategic shift is toward higher-growth oncology, multispecialty, and biopharma services while simplifying the portfolio through the European exit and planned Medical-Surgical separation.

Business Models: How Cardinal Health, Inc. and McKesson Corporation Make Money

Cardinal Health, Inc. and McKesson Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and McKesson Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

McKesson Corporation business model: McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results. The company also earns service revenue through oncology and multispecialty provider platforms, biopharma services, prescription access and affordability tools, third-party logistics, and medical-surgical distribution.

Competitive Advantage: Cardinal Health, Inc. vs McKesson Corporation

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of McKesson Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

McKesson Corporation competitive advantage: McKesson's advantage is the combination of distribution scale, regulated logistics, supplier and customer relationships, specialty capabilities, and nationwide infrastructure. Those assets are expensive and difficult to replicate, but large customers retain negotiating power and the core distribution model remains sensitive to small changes in pricing, product mix, and costs.

Growth Strategy: Where Cardinal Health, Inc. and McKesson Corporation Are Headed

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and McKesson Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

McKesson Corporation growth strategy: McKesson is concentrating capital on oncology, multispecialty care, and biopharma services, where provider relationships and specialty capabilities can grow faster than traditional wholesale distribution. It is also expanding prescription access and affordability services, completing its exit from Europe, and pursuing a separation of Medical-Surgical Solutions. The objective is a more focused portfolio with better profit growth while preserving the reliability and cash generation of North American pharmaceutical distribution.

Financial Picture: Cardinal Health, Inc. vs McKesson Corporation

A closer look at the financial trajectory of Cardinal Health, Inc. and McKesson Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%. Cardinal Health is a colossal healthcare services and logistics company, maintaining a market valuation generally exceeding $25 billion.

McKesson Corporation: McKesson reported fiscal 2026 revenue of $403.4 billion, up 12%, operating cash flow of $6.2 billion, and free cash flow of $5.4 billion. North American Pharmaceutical produced $336.7 billion of revenue; Oncology & Multispecialty produced $48.4 billion; Prescription Technology Solutions produced $5.8 billion; and Medical-Surgical Solutions produced $11.5 billion. Revenue should be read alongside segment profit and cash flow because distribution and retail represented about 98% of consolidated revenue but operate on thin margins.

Company-Specific SWOT Notes

Cardinal Health, Inc.

Strength

Cardinal Health, McKesson, and Cencora control well over 90% of the U.S. pharmaceutical wholesale market, creating barriers to entry that new competitors cannot overcome within a decade.

Strength

The 50/50 joint venture with CVS Health, established in 2014, is one of the largest generic drug buyers in the United States, negotiating supply contracts for over 9,000 CVS retail locations, Caremark mail-order facilities, and Cardinal Health's distribution n

Weakness

The OptumRx contracts represented about $38.1 billion of fiscal 2024 revenue before they expired in June 2024, and CVS Health remains a major customer and Red Oak Sourcing partner.

Weakness

Pharmaceutical and Specialty Solutions generated $234.8 billion of fiscal 2026 revenue but $2.8 billion of segment profit, a margin of about 1.2%.

Opportunity

Cardinal Health has built physician-facing platforms in gastroenterology (GI Alliance, 71% stake for about $2.8 billion), urology (Solaris Health through The Specialty Alliance, about $1.9 billion), and oncology (Integrated Oncology Network), plus ADSG in diab

Threat

Generic pharmaceutical prices generally decline over time as additional manufacturers enter the market, and the frequency of generic price appreciation events, where limited competition allows prices to rise, has decreased.

McKesson Corporation

Strength

One of three U.S. wholesalers with full national scale, giving McKesson purchasing leverage, generic sourcing power and daily reach to pharmacies and providers.

Strength

The US Oncology Network, CoverMyMeds and Health Mart tie McKesson into practice, pharmacy and prior-authorization workflows that are costly for customers to switch.

Weakness

Net margin was about 1.2% in fiscal 2026, and a small number of large pharmacy and PBM customers account for a significant share of revenue.

Opportunity

Specialty drug volumes and acquisitions such as Florida Cancer Specialists' Core Ventures and PRISM Vision expand higher-margin specialty services.

Threat

Medicare price negotiation, 340B disputes, generic deflation and changes to PBM economics could pressure distributor compensation.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScaleMcKesson Corporation$254.2B (FY2026) versus $403.4B (FY2026); the higher figure is identified after approximate USD conversion.
Founded EarlierMcKesson CorporationCardinal Health, Inc. was founded in 1971; McKesson Corporation was founded in 1833.
Verdict

Comparison Takeaway: Cardinal Health vs McKesson

Cardinal Health actually grew faster in fiscal 2026, with revenue up 14.2% to $254.2 billion versus McKesson's 12.4% increase to $403.4 billion, as brand and specialty drug volumes rebounded after Cardinal Health lost the roughly $38.1 billion OptumRx contract in June 2024. McKesson's advantage is efficiency and scale: it runs a 43,000-person workforce to Cardinal Health's 63,900, and its market capitalization of roughly $102 billion was nearly double Cardinal Health's roughly $56 billion as of September 2026. Both companies are chasing the same escape from thin wholesale margins by buying physician-practice platforms, Cardinal Health through its 71% stake in GI Alliance and The Specialty Alliance's acquisition of Solaris Health, McKesson through Florida Cancer Specialists' Core Ventures and PRISM Vision Holdings, but McKesson is simultaneously shrinking by spinning off Medical-Surgical Solutions as 'Wellverse' after selling Apollo Funds a 13% stake for $1.25 billion, while Cardinal Health is still building out its specialty and nuclear-pharmacy mix rather than divesting units. On every absolute measure McKesson remains the stronger business today, but Cardinal Health's faster fiscal 2026 growth under CEO Jason Hollar has narrowed the gap more than the headline revenue numbers suggest.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: Cardinal Health vs McKesson

Is Cardinal Health or McKesson bigger?

McKesson is bigger by every major financial measure. It reported $403.4 billion in revenue for fiscal 2026 (ended March 31, 2026), compared with Cardinal Health's $254.2 billion for its fiscal 2026 (ended June 30, 2026), a gap of about $149 billion. McKesson's market capitalization of roughly $102 billion was also nearly double Cardinal Health's roughly $56 billion as of September 2026.

Which company is more profitable, Cardinal Health or McKesson?

McKesson is more profitable on every measure. It earned $4.76 billion in net income on $403.4 billion of fiscal 2026 revenue, a net margin of about 1.18%, versus Cardinal Health's $1.71 billion in net income on $254.2 billion of revenue, a margin of about 0.67%. Both margins stay thin because wholesale drug distribution runs on volume rather than markup.

Who are the CEOs of Cardinal Health and McKesson?

Jason M. Hollar has been CEO of Cardinal Health since September 1, 2022, after serving as the company's CFO starting in May 2020; he was previously CFO of Tenneco. Brian S. Tyler has been CEO of McKesson since April 2019, having joined the company in 1997 and risen through its president and chief operating officer roles.

How are Cardinal Health and McKesson expanding beyond drug distribution?

Both are buying physician-practice platforms to escape thin wholesale margins, but moving in opposite directions on scale. Cardinal Health bought a 71% stake in GI Alliance and completed The Specialty Alliance's roughly $1.9 billion Solaris Health urology acquisition in November 2025, adding to its existing segments. McKesson, by contrast, sold Apollo Funds a 13% stake in its Medical-Surgical Solutions unit for $1.25 billion in 2026 and plans to spin that business off entirely as an independent company called Wellverse, even as it adds oncology practices like Florida Cancer Specialists' Core Ventures to The US Oncology Network.

Which is better, Cardinal Health or McKesson?

McKesson is the stronger company today on scale, profitability, and market value: $403.4 billion in fiscal 2026 revenue, a 1.18% net margin, and about $102 billion in market capitalization versus Cardinal Health's $254.2 billion, 0.67% margin, and roughly $56 billion in market value. Cardinal Health is the one to watch for growth, though, since it grew revenue 14.2% in fiscal 2026, outpacing McKesson's 12.4%, as it recovered from losing the $38.1 billion OptumRx contract in 2024.

Which company was founded first, Cardinal Health, Inc. or McKesson Corporation?

McKesson Corporation was founded in 1833; Cardinal Health, Inc. was founded in 1971.

What revenue did Cardinal Health, Inc. and McKesson Corporation report?

Cardinal Health, Inc. had $254.2B (FY2026), while McKesson Corporation had $403.4B (FY2026). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do Cardinal Health, Inc. and McKesson Corporation make money?

Cardinal Health, Inc.: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. McKesson Corporation: McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers.

Which is better, Cardinal Health, Inc. or McKesson Corporation?

There is no evidence-based single winner. Compare Cardinal Health, Inc. and McKesson Corporation on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

McKesson is bigger than Cardinal Health by revenue and profit: $403.4 billion in revenue and $4.76 billion in net income for fiscal 2026 (ended March 31, 2026), versus Cardinal Health's $254.2 billion in revenue and $1.71 billion in net income for its fiscal 2026 (ended June 30, 2026). McKesson also converts more of each sales dollar into profit, with a net margin near 1.18% against Cardinal Health's roughly 0.67%. Cardinal Health employs more people (63,900) than McKesson (about 43,000) despite having smaller revenue, so McKesson produces substantially more revenue per employee.

Verdict

Cardinal Health actually grew faster in fiscal 2026, with revenue up 14.2% to $254.2 billion versus McKesson's 12.4% increase to $403.4 billion, as brand and specialty drug volumes rebounded after Cardinal Health lost the roughly $38.1 billion OptumRx contract in June 2024. McKesson's advantage is efficiency and scale: it runs a 43,000-person workforce to Cardinal Health's 63,900, and its market capitalization of roughly $102 billion was nearly double Cardinal Health's roughly $56 billion as of September 2026. Both companies are chasing the same escape from thin wholesale margins by buying physician-practice platforms, Cardinal Health through its 71% stake in GI Alliance and The Specialty Alliance's acquisition of Solaris Health, McKesson through Florida Cancer Specialists' Core Ventures and PRISM Vision Holdings, but McKesson is simultaneously shrinking by spinning off Medical-Surgical Solutions as 'Wellverse' after selling Apollo Funds a 13% stake for $1.25 billion, while Cardinal Health is still building out its specialty and nuclear-pharmacy mix rather than divesting units. On every absolute measure McKesson remains the stronger business today, but Cardinal Health's faster fiscal 2026 growth under CEO Jason Hollar has narrowed the gap more than the headline revenue numbers suggest.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). Cardinal Health, Inc. vs McKesson Corporation Comparison. from https://corpdigest.com/compare/cardinal-health-vs-mckesson

MLA Format

CorpDigest. "Cardinal Health, Inc. vs McKesson Corporation Comparison." CorpDigest, 2026, https://corpdigest.com/compare/cardinal-health-vs-mckesson.

Chicago Format

CorpDigest. "Cardinal Health, Inc. vs McKesson Corporation Comparison." CorpDigest. 2026. https://corpdigest.com/compare/cardinal-health-vs-mckesson.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.